Partial agonism at nicotinic receptors with varenicline--a new approach to smoking cessation

Comment

. 2006 Dec;7(18):2599-603.

doi: 10.1517/14656566.7.18.2599.

Affiliations

¹ School of Science, Faculty of Education, Health and Science, Charles Darwin University, Darwin, Northern Territory 0909, Australia. sheila.doggrell@cdu.edu.au

Comment

Sheila A Doggrell. Expert Opin Pharmacother. 2006 Dec.

. 2006 Dec;7(18):2599-603.

doi: 10.1517/14656566.7.18.2599.

¹ School of Science, Faculty of Education, Health and Science, Charles Darwin University, Darwin, Northern Territory 0909, Australia. sheila.doggrell@cdu.edu.au

No abstract available

Comment on

Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial.
Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, Watsky EJ, Gong J, Williams KE, Reeves KR; Varenicline Phase 3 Study Group. Gonzales D, et al. JAMA. 2006 Jul 5;296(1):47-55. doi: 10.1001/jama.296.1.47. JAMA. 2006. PMID: 16820546 Clinical Trial.
Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial.
Tonstad S, Tønnesen P, Hajek P, Williams KE, Billing CB, Reeves KR; Varenicline Phase 3 Study Group. Tonstad S, et al. JAMA. 2006 Jul 5;296(1):64-71. doi: 10.1001/jama.296.1.64. JAMA. 2006. PMID: 16820548 Clinical Trial.
Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation.
Oncken C, Gonzales D, Nides M, Rennard S, Watsky E, Billing CB, Anziano R, Reeves K. Oncken C, et al. Arch Intern Med. 2006 Aug 14-28;166(15):1571-7. doi: 10.1001/archinte.166.15.1571. Arch Intern Med. 2006. PMID: 16908789 Clinical Trial.